Abstract: Drug combinations, compositions including pharmaceutical compositions as well as methods of using and treating a viral infection, including one of the following: (1) atovaquone with a second group of substances consisting of ademetionine, albendazole, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, niclosamide, raloxifene, sorafenib, and tipifarnib; or (2) cepharantine with a second group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, and tipifarnib; or (3) one substance selected from a first group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progester

Abstract: Drug combinations, compositions including pharmaceutical compositions as well as methods of using and treating a viral infection, the drug combinations including (1) protease inhibitors Camostat, Nafamostat, (2) modulators or inhibitors of intracellular steroid hormone receptors signaling pathways (steroid hormone receptor antagonists), (3) modulators or inhibitors of SKP2 protein, (4) modulators of poly(ADP-ribose) polymerases and (5) angiotensin 2 response modifiers.

Abstract: The disclosed subject matter relates to the construction and use of novel proteomics-based descriptor sets for analyzing high throughput proteomics derived pathogen-host interactome information and the use of these descriptor sets for identifying substances and substance combinations that have utility for treating and or preventing infections and diseases caused by a broad range of pathogens of diverse origins.

Abstract: The present disclosure relates to pharmaceutical compositions, pharmaceutical combinations and methods of treatment including zileuton, edaravone and atorvastatin compounds combined with nephrotoxicity-inducing antibiotic or anticancer drugs for treating bacterial infections and cancers.

Abstract: A method of tracking information flows through multiple network systems includes selecting a primary network system from a population of primary and secondary network systems, wherein each of the primary and secondary network systems include network nodes, selecting first selected characteristic features that identify network nodes of the primary network system that provide interaction between the selected primary network system and secondary network systems, identifying at least one secondary network system that is capable of interacting with the network nodes of the primary network system, subdividing the primary network into subnetwork systems based on identifying primary network nodes that provide interaction between the primary network system and secondary network nodes, identifying the subnetwork systems that are capable of interacting with one or more network nodes of the secondary network systems, identifying a subnetwork node count of the primary network nodes in each subnetwork, identifying objects

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The aspects of the disclosed embodiments are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.

Abstract: A method of tracking information flows through multiple network systems includes selecting a primary network system from a population of primary and secondary network systems, wherein each of the primary and secondary network systems include network nodes, selecting first selected characteristic features that identify network nodes of the primary network system that provide interaction between the selected primary network system and secondary network systems, identifying at least one secondary network system that is capable of interacting with the network nodes of the primary network system, subdividing the primary network into subnetwork systems based on identifying primary network nodes that provide interaction between the primary network system and secondary network nodes, identifying the subnetwork systems that are capable of interacting with one or more network nodes of the secondary network systems, identifying a subnetwork node count of the primary network nodes in each subnetwork, identifying objects

Abstract: The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.

Abstract: The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): 1

Abstract: The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.

Abstract: The present invention provides diazabicyclooctane derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein the group represents R1 and R2 are selected independently from H, (C1-C6)alkyl, (C1-C6)fluoroalkyl, halogen (e.g., F.

Abstract: The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): pharmaceutically acceptable salts thereof, wherein A is (CH2)n where n is equal to 0, 1 or 2; U is CH2, NH, or NR3, R1 and R2 are selected independently from H, (C1-C6)alkyl, Cl, F, CN, nitro, CF3, —NHC(O)R6 and —OR7, or R1 and R2, together with the atoms to which they are attached, form a carbocyclic or heterocyclic five- or six-membered ring, R3 is selected from the group consisting of H, (C1-C6)malkyl, C(═O)—(C1-C6)alkyl, where m=1 or 2; R4 and R5 are selected from H, (C1-C6)alkyl, Cl, F, —CF3, —CN, —NHC(═O)R6, —OR7, a 5-to 7-membered aryl or heteroaryl ring, where m, R6 and R7 are as defined above; and R6 and R7 are selected independently from H, (C1-C6)alkyl or a 5- to 7-membered aryl or heteroaryl ring; V is CH, CR3, or N; W is CH2, C(O), or S(O)2; X is C or N; and Y is CH, CR1,CR2, or N.